Biogen is acquiring Apellis Pharmaceuticals in a $5.6 billion deal that brings two FDA-approved products commercialized in four indications, all of which are expected to contribute to the revenue ...

This story is republished from STAT, the health and medicine news site that’s a partner to the Globe. Sign up for STAT’s free Morning Rounds newsletter here. Biogen said Tuesday that it would buy ...

Investing.com - BMO Capital reiterated a Market Perform rating on Biogen Inc. (NASDAQ:BIIB) with a $196.00 price target following the company’s acquisition of Apellis. The stock currently trades at ...

When you purchase through links on our site, we may earn an affiliate commission. Here’s how it works. Why you can trust What Hi-Fi? Our expert team reviews products in dedicated test rooms, to help ...

Investing.com - Stifel maintained its Buy rating and $214.00 price target on Biogen stock (NASDAQ:BIIB) following the company’s acquisition of Apellis. The stock currently trades at $178.64, with ...

This move follows Biogen’s earlier purchase of Hi-Bio, further expanding its commercial franchise in nephrology. These developments mark a significant strategic shift for Biogen as it broadens its ...

Iptacopan significantly slowed kidney function decline over 24 months compared with placebo in adults with IgA nephropathy. The complement inhibitor was granted accelerated approved in 2024; continued ...

Hisense is very good at making budget televisions – just look at the U7K. Value is the name of the game, and Hisense is able to pack it in to a degree no one else is coming close to hitting. It starts ...